QUINSAIR 240 MG / 2.4 ML
LEVOFLOXACIN (LEVOFLOXACIN HEMIHYDRATE) : 240 MG / 2.4 ML · DIN 02442302 · HORIZON THERAPEUTICS IRELAND DAC
Health Canada status: MARKETED
What is QUINSAIR?
QUINSAIR 240 MG / 2.4 ML contains LEVOFLOXACIN (LEVOFLOXACIN HEMIHYDRATE) : 240 MG / 2.4 ML. It is listed in the Health Canada Drug Product Database under DIN 02442302, held by HORIZON THERAPEUTICS IRELAND DAC, supplied as SOLUTION for INHALATION administration. Health Canada currently lists it as marketed, status dated 24-Aug-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is QUINSAIR used for?
Management of cystic fibrosis in patients aged 18 years or older with chronic pulmonary Pseudomonas aeruginosa infections.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02442302 |
|---|---|
| Brand name | QUINSAIR |
| Generic / active ingredient | LEVOFLOXACIN (LEVOFLOXACIN HEMIHYDRATE) : 240 MG / 2.4 ML |
| Manufacturer | HORIZON THERAPEUTICS IRELAND DAC |
| Strength | 240 MG / 2.4 ML |
| Dosage form | SOLUTION |
| Route of administration | INHALATION |
| Schedule | Prescription |
| ATC code | J01MA12 LEVOFLOXACIN |
| AHFS class | 08:12.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Aug-2026 |
| Original market date | 2016-12-12 00:00:00 |
How is it administered?
240 mg (one 2.4 mL ampoule) inhaled twice daily using the ZIRELA Nebulizer System. Administered in cycles of 28 days on treatment followed by 28 days off treatment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (implied by standard summary, though snippet ends before specific storage section).
How is it supplied?
240 mg/2.4 mL (100 mg/mL) ampoules. (Full details not in snippet, but strength/volume provided).
Contraindications
Hypersensitivity to levofloxacin, quinolones, or components; history of tendinitis or tendon rupture associated with quinolone use.
Warnings and precautions
Disabling/persistent reactions: tendinitis, tendon rupture, peripheral neuropathy, neuropsychiatric effects. QT prolongation, hepatotoxicity, and exacerbation of myasthenia gravis.
Is LEVOFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by PFIZER CANADA ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01MA12 LEVOFLOXACIN. 16 of 54 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT LEVOFLOXACIN | 250 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02315424 |
| ACT LEVOFLOXACIN | 500 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02315432 |
| ACT LEVOFLOXACIN | 750 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02315440 |
| APO-LEVOFLOXACIN | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02284707 |
| APO-LEVOFLOXACIN | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02284715 |
| APO-LEVOFLOXACIN | 750 MG | TABLET | APOTEX INC | MARKETED | DIN 02325942 |
| JAMP LEVOFLOXACIN | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02508443 |
| JAMP LEVOFLOXACIN | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02508451 |
| JAMP LEVOFLOXACIN | 750 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02508478 |
| LEVOFLOXACIN | 500 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02415879 |
Who else supplies LEVOFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVOFLOXACIN appears in 269 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.